{"id":"flupenthixol","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"D(1B) dopamine receptor, D(4) dopamine receptor, Solute carrier family 22 member 1"},"_scrapedAt":"2026-03-28T03:32:10.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Schizophrenia","diseaseId":"schizophrenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05766007","phase":"","title":"Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-08-01","conditions":"Schizophrenia, Psychosis, Mania","enrollment":125},{"nctId":"NCT06945237","phase":"NA","title":"Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2025-04-24","conditions":"Gastroesophageal Reflux Disease","enrollment":164},{"nctId":"NCT03513185","phase":"","title":"Assessment of SSD in Outpatients Using SSS-CN","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-09-01","conditions":"Somatization Disorder","enrollment":1863},{"nctId":"NCT06756139","phase":"NA","title":"Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-11-01","conditions":"Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug","enrollment":88},{"nctId":"NCT06931223","phase":"NA","title":"Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-10","conditions":"Functioanl Dyspepsia","enrollment":200},{"nctId":"NCT06927375","phase":"PHASE4","title":"A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2024-12-12","conditions":"Thyroid-Associated Ophthalmopathy","enrollment":60},{"nctId":"NCT03472651","phase":"PHASE1","title":"Bioequivalence Study to Compare Two Formulations of Deanxit®","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-05-07","conditions":"Healthy","enrollment":60},{"nctId":"NCT05099913","phase":"NA","title":"The Role of Neuromodulators in Refractory Functional Dyspepsia","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-08-01","conditions":"Dyspepsia, Functional Gastrointestinal Disorders, Antidepressant Discontinuation Syndrome","enrollment":220},{"nctId":"NCT04970667","phase":"PHASE4","title":"Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2018-01-01","conditions":"Emotional Disorder, Neurologic Disorder","enrollment":100},{"nctId":"NCT04898270","phase":"PHASE4","title":"Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2019-12-19","conditions":"Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol","enrollment":30},{"nctId":"NCT02723903","phase":"PHASE1, PHASE2","title":"Hierarchical Treatment Based on Somatization Symptom Checklist","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2015-12","conditions":"Syndrome X","enrollment":200},{"nctId":"NCT03600974","phase":"","title":"A New System for GERD Diagnosis and Treatment","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2019-02-01","conditions":"GERD","enrollment":200},{"nctId":"NCT03205228","phase":"PHASE3","title":"Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-07","conditions":"Globus","enrollment":40},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00000274","phase":"PHASE2","title":"Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1997-03","conditions":"Cocaine-Related Disorders, Substance-Related Disorders","enrollment":60},{"nctId":"NCT00000266","phase":"PHASE2","title":"Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1994-08","conditions":"Cocaine-Related Disorders","enrollment":""},{"nctId":"NCT00000241","phase":"PHASE2","title":"Flupenthixol Decanoate in Methamphetamine Smoking - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1994-02","conditions":"Substance-Related Disorders","enrollment":58},{"nctId":"NCT00000275","phase":"PHASE2","title":"Cocaine Abuse and ADHD - 10","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-11","conditions":"Cocaine-Related Disorders","enrollment":16},{"nctId":"NCT00000349","phase":"PHASE1","title":"Infusion Laboratory: Protocol 5 (Flupenthixol) - 14","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"","conditions":"Cocaine-Related Disorders","enrollment":""},{"nctId":"NCT02660840","phase":"PHASE1","title":"Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-01","conditions":"Bioequivalence Study in Healthy Subjects","enrollment":84},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT01164059","phase":"PHASE4","title":"Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia","status":"COMPLETED","sponsor":"University of Bremen","startDate":"2010-02","conditions":"Schizophrenia","enrollment":149},{"nctId":"NCT01851863","phase":"PHASE4","title":"Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2013-05","conditions":"Dyspepsia, Compliance, Depression","enrollment":262},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT02179931","phase":"PHASE1","title":"Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-06","conditions":"Healthy Men and Women","enrollment":30},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00841230","phase":"PHASE4","title":"Deanxit and Rivotril in Tinnitus Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2009-02","conditions":"Tinnitus","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":942,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Flupenthixol","genericName":"Flupenthixol","companyName":"National Institute on Drug Abuse (NIDA)","companyId":"national-institute-on-drug-abuse-nida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}